Document is current
Any future updates will be listed below
-
Authors
Beyerstedt, Stephany
Franco, Marcella L.
Carlos, Alanah K. G.
Arjona, Jaqueline
Josefi-Rocha, Gleice R.
Barbosa, Bruno S.
Balby-Rocha, Maria Theresa A.
da Silva, Andrei Furlan
Alves, Tuany Marques Reiter
Mariano, Melise Oliveira
Klein, Maria Clara Soares
Rangel, Érika Bevilaqua https://orcid.org/0000-0003-0982-2484
-
Funding
Funding for this research was provided by:
Fundação de Amparo à Pesquisa do Estado de São Paulo (2017/23195-2, 2021/02216-7, 2019/12636-3, 2024/08173-6)
European Foundation for the Study of Diabetes
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- License Information
-
More Information
Article History
Received: 8 March 2024
Accepted: 23 April 2025
First Online: 20 May 2025
Declarations
:
: The authors declare no competing interests.
: Not applicable.
: This research does not contain clinical experiments. All the experiments are approved under the projects “Treatment with empagliflozin, mesenchymal stem cells, and klotho as measures to slow down the progression of diabetic kidney disease and reduce the impact of acute kidney injury” and “Fat transplantation as a routine procedure to increase the number of BTBRob/ob mice in the animal facility” by the Institutional Animal Care and and Use Committee of Hospital Israelita Albert Einstein (HIAE). The approval numbers are SGPP 4900–21 (data of approval: August 27th, 2021) and SGPP 5171–22 (data of approval: April 29th, 2022), respectively. Our manuscript is reported following the ARRIVE guidelines.
